The hypothesis suggests that tirzepatide's dual GIP and GLP‐1 agonism creates a potent metabolic effect that could be leveraged to treat obesity by promoting fat loss and improving insulin sensitivity. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.